Research paperRandomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia

Add time:08/30/2019    Source:sciencedirect.com

PurposeCytosine arabinoside (AraC) remains the backbone of most treatment regimens for acute myeloid leukemia (AML). Incorporation of AraC into DNA activates checkpoint kinase 1 (Chk1), leading to cell-cycle arrest and diminished AraC cytotoxicity, which can be reversed by the selective Chk1 inhibitor MK-8776. Building on a Phase I trial, we conducted a phase II trial comparing timed sequential AraC with or without MK-8776.

We also recommend Trading Suppliers and Manufacturers of N(4)-chloroacetylcytosine arabinoside (cas 113737-52-3). Pls Click Website Link as below: cas 113737-52-3 suppliers

Prev:Recent and remote spatial memory in mice treated with cytosine arabinoside
Next:Amino acid sulfones: S-Benzyl-dl-α-methylcysteine sulfone)